Menu Menu

News

Topics
Featured
COVID-19 Research Pipeline

190,093

Registered/ Published

4,540

Registered

753

Published

7,055

Registered
As at 02 December 2022
FILTERED BY > Tocilizumab Clear filter

Communique #55

17 December, 2021
Click for the latest Taskforce news:
Communique

Communique #52

29 October, 2021
Click for the latest Taskforce news:
Communique

Communique #48

5 August, 2021
WEEK IN REVIEW Taskforce amends remarks for Tocilizumab in response to critical shortage This week the Taskforce was alerted by the Therapeutic Goods Administration (TGA) to a global tocilizumab shortage...
Communique

Taskforce amends remarks for Tocilizumab in response to critical shortage

5 August, 2021
This week the Taskforce was alerted by the Therapeutic Goods Administration (TGA) to a global tocilizumab shortage for both COVID-19 treatment use and other indications. To help support...
News

EXPLAINER: What happens if I test positive to COVID-19?

19 July, 2021
With the recent COVID-19 outbreak in NSW and Victoria, it’s timely to revisit what happens if you test positive with COVID-19.  With so much media commentary and coverage...
Explainer

Guidelines update, v38.3

13 May, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   Convalescent plasma...
News

Communique #42

22 April, 2021
Message from the Chair and Executive Director Dear Colleagues We’ve just passed 12-months since the first publication of the Australian clinical guidelines for the care of people with COVID-19....
Communique

Communique #40

18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique

Guidelines update, v35.2

11 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:   Tocilizumab - The reference for one included study (Wang et al.) was...
News

Guidelines update, v35.1

4 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...
News

Communique #39

25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique

RECOVERY Trial publishes tocilizumab results

12 February, 2021
The Taskforce notes the publication of results of the tocilizumab arm of the RECOVERY trial in medRxiv Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results...
News

Communique #38

11 February, 2021
Message from the Taskforce Chair Dear colleagues As we enter the second year of the COVID-19 pandemic it is timely to acknowledge the important role of the Taskforce’s...
Communique

Communique #37

29 January, 2021
Following a well-earned break, the Taskforce team has now returned to full capacity. Global evidence surveillance continued throughout January, with six clinical panel meetings held since January 11....
Communique

Taskforce recommendation for tocilizumab unchanged

29 January, 2021
The Taskforce Disease Modifying Treatments and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated the results of the tocilizumab arm of the REMAP-CAP trial (published as a pre-print on January 7,...
News